Venous Thromboembolism Clinical Trial
— SYMPTOMSOfficial title:
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Verified date | June 2022 |
Source | University Hospital, Brest |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Venous thromboembolism (VTE) is a frequent condition, affecting 1.8 per 1,000 people every year. Admission to hospital is one of the main risk factors for VTE, and could account for up to 20% of all VTE, making VTE prevention in admitted patients an appealing option to reduce VTE global burden. The landmark MEDENOX trial and others demonstrated the efficacy of low molecular weight heparins (LMWH) in reducing a composite outcome of symptomatic and asymptomatic events, the latter accounting for the vast majority of events. Publication of these trials led to the implementation of thromboprophylaxis policies in hospitals, which acceptance has been variable. More recently, the use of thromboprophylaxis has been challenged after the publication of 1) a negative trial that used 'death from any cause' as main outcome, 2) a systematic review showing the lack of a clear efficacy on the risk of pulmonary embolism or death, 3) negative trials using new oral anticoagulants, 4) the last version of the American College of Chest Physicians Guidelines, focusing on symptomatic events only, downgraded its recommendation for thromboprophylaxis in medical patients to a 1B recommendation, restricting its use to patients 'at increased risk of thrombosis' and recommending against the use of thromboprophylaxis in patients at low risk of thrombosis, patients bleeding or at high risk of bleeding. However, a limitation of this interpretation of the data is that in most trials, patients with screened asymptomatic events were treated with anticoagulants, preventing the occurrence of symptomatic events during follow-up. Moreover, subgroup analyses showed that elderly patients were at high risk of thrombosis in these trials, and that LMWH could be particularly efficient in this subgroup of patients. Conversely, their risk of bleeding is also higher than in younger patients and the current trials were not powered to detect a difference in the bleeding risk between groups. Finally, the diagnostic and therapeutic management of VTE is more challenging in the elderly. Therefore, we planned a randomized controlled trial on the efficacy of LMWH for the prevention of symptomatic VTE in elderly patients.
Status | Completed |
Enrollment | 2560 |
Est. completion date | December 29, 2020 |
Est. primary completion date | December 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years and older |
Eligibility | Inclusion Criteria: - Patient aged 70 years or older - Admitted to hospital for an acute medical illness - Anticipated duration of hospitalization of at least 4 days - Life expectancy of at least 3 months Exclusion Criteria: - Admission for one of the following reasons: - Planned medical procedure. - Routine health assessment requiring admission for baseline/trending of health status (e.g., routine colonoscopy). - Admission encountered for another life circumstance that causes no bearing on health status and requires no medical intervention (e.g., lack of housing, economic inadequacy, care-giver respite, family circumstances, administrative). - Hypersensitivity to heparin - History of Heparin Induced Thrombocytopenia - Active bleeding - Bacterial endocarditis - Platelet count of less than 80,000 per cubic millimeter - Patients who require anticoagulant therapy for any indication, and those who received any type of anticoagulant therapy for > 48 hours - Organic lesion prone to bleeding. - Hemorrhagic events or bleeding tendency due to hemostasis disorders. - Concomitant use of aspirin (> 160 mg/day), clopidogrel (> 75 mg/day), or of combined antiplatelet therapy - Creatinine clearance < 15 ml/min - Unable or unwilling to consent - Ischemic stroke + hemorrhagic transformation - Patient requiring admission to Intensive Care Unit |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier d'Agen | Agen | |
France | CHU Angers | Angers | |
France | CH Angoulême | Angouleme | |
France | CH d'Arras | Arras | |
France | CH Béthune | Béthune | |
France | Hôpital Jean Verdier (APHP) | Bondy | |
France | CHU Bordeaux | Bordeaux | |
France | CHRU Brest | Brest | |
France | HIA Clermont-Tonnerre | Brest | |
France | CH Public du Cotentin | Cherbourg | |
France | CH Louis Mourier de Colombes | Colombes | |
France | CHU de Dijon | Dijon | |
France | CHU Grenoble | Grenoble | |
France | CHD Vendée | La Roche Sur Yon | |
France | Groupe Hospitalier Le Havre | Le Havre | |
France | CHU Rouen | Le Petit Quevilly | |
France | CHRU de Lille | Lille | |
France | CHU Limoges | Limoges | |
France | CHD Vendée - Site de Luçon | Luçon | |
France | CHU Lyon | Lyon | |
France | Hôpital Edouard Herriot - CHU Lyon | Lyon | |
France | Hôpital de la Timone - AP-HM | Marseille | |
France | Clinique Mutualiste Médico-chirurgical "Beau Soleil" | Montpellier | |
France | CH des Pays de Morlaix | Morlaix | |
France | CHU Nancy | Nancy | |
France | CHU de Nantes | Nantes | |
France | Hôpital Cimiez - CHU Nice | Nice | |
France | HEGP - Paris | Paris | |
France | Hôpita Cochin - APHP | Paris | |
France | Hôpital Broca- APHP | Paris | |
France | Hôpital Lariboisiere | Paris | |
France | Hôpital Saint-Antoine (APHP) | Paris | |
France | Institut Mutualiste Montsouris | Paris | |
France | CH Périgueux | Perigueux | |
France | CHU Poitiers | Poitiers | |
France | CH de Cornouaille - Quimper | Quimper | |
France | CHU Rennes | Rennes | |
France | Hôpital Charles Nicolle- CHU Rouen | Rouen | |
France | CHU La Réunion - Site Félix Guyon | Saint Denis | |
France | CHU de Saint Etienne | Saint Etienne | |
France | CHU La Réunion - site du GHSR | Saint Pierre | |
France | CHRU Strasbourg- Service HTA et Maladies Vasculaires | Strasbourg | |
France | CHU Strasbourg - Service de Médecine Interne | Strasbourg | |
France | CH Intercommunal Toulon La Seyne sur Mer | Toulon | |
France | HIA Sainte-Anne Toulon | Toulon | |
Switzerland | Hôpitaux Universitaires de Genève | Genève |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Brest |
France, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurence of the following events: symptomatic confirmed deep venous thrombosis (DVT), symptomatic confirmed pulmonary embolism (PE), or fatal PE | Occurence of any of the events through the Day 30 visit | ||
Secondary | Occurence of the following events: Major bleeding, clinically relevant non major bleeding, symptomatic confirmed VTE (DVT or PE) or fatal PE, atherothrombotic cardiovascular events, cardiovascular death, Death from any cause. | The secondary outcomes is the occurrence of any of the following events:
Major bleeding as defined by the criteria of the International Society of Thrombosis and Haemostasis at day 30 and day 90 Clinically relevant non major bleeding and any bleeding at day 30 and day 90 Symptomatic confirmed VTE (DVT or PE) or fatal PE through the day 90 visit Atherothrombotic cardiovascular events at day 30 and day 90 Cardiovascular death at day 30 and day 90 Death from any cause at day 30 and day 90 Rate of VTE and bleeding events at day 30 and day 90 according to creatinin clearance (< 50 ml/min and = 50 ml/min), age range, D-dimer level and the use or not of antiplatelet therapy to identified the population at risk for VTE and bleeding. |
Occurence of any of the events through the Day 30 and Day 90 visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05347550 -
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
|
N/A | |
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Recruiting |
NCT03691753 -
Safety and Efficacy Study of Fitaya Vena Cava Filter
|
N/A | |
Completed |
NCT02197416 -
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
|
Phase 3 | |
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT01895777 -
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
|
Phase 3 | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Completed |
NCT04736420 -
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04735523 -
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736719 -
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT02829957 -
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
|
Phase 2/Phase 3 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02912234 -
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02223260 -
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
|
Phase 2 | |
Completed |
NCT02661568 -
Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)
|
N/A | |
Completed |
NCT01976988 -
Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
|
Phase 3 | |
Completed |
NCT01972243 -
Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model
|
||
Completed |
NCT01431456 -
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
|
Phase 3 |